How much does it cost to treat amivantamab for one month and its cost structure

As a new bispecific antibody drug, amivantamab is mainly used to treat patients with non-small cell lung cancer with specific gene mutations. Due to its innovative targeting mechanism and good efficacy, it has attracted much attention in recent years. The drug has just been launched in China and has been on the market for a short time. It has not yet been popularized throughout the country. Therefore, many patients may not be able to purchase it directly through domestic channels for the time being.

From a price perspective, the specific cost of evantumumab in China is not yet completely clear, mainly because it has just been launched and is not yet covered by medical insurance. If patients need to use the drug as soon as possible, they often consider purchasing it from overseas markets. As a relatively mature medical market, Hong Kong, China, currently has an anti-drug version of Evantum available, with a price of approximately RMB 10,000 per month. This price is mainly calculated based on the specifications and dosage standards of the drug.

The cost structure of evantumumab mainly includes the purchase cost of the drug itself, possible logistics and transportation costs, import duties, etc. Especially when purchasing the drug through overseas channels, these additional costs may increase the patient's overall medication burden. In addition, since the drug is in the form of intravenous injection, the medication process may also involve hospital injection fees and related nursing fees, which require patients to budget and consult in advance.

Overall, evantumumab, as a newly launched targeted therapy drug, has a relatively high price and limited purchasing channels. Patients need to fully understand the cost structure and accessibility before taking the drug, and make reasonable choices based on their own economic status and treatment needs. At the same time, with the extension of domestic market time and the improvement of medical insurance policies, the cost of evantumumab is expected to be further reduced in the future, helping more patients obtain timely and effective treatment.

Reference materials:https://www.rybrevant.com/